Evidence map›Paper›PMID 26535145›Full record

ArticleRMD open2015

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts.

Ana Maria Gherghe, Maxime Dougados, Bernard Combe, Robert Landewé, Carina Mihai, Francis Berenbaum, Xavier Mariette, Ron Wolterbeek, Désirée van der Heijde

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Ana Maria GhergheDepartment of Rheumatology , Leiden University Medical Centre , Leiden , The Netherlands ; Department of Internal Medicine and Rheumatology , Cantacuzino Clinical Hospital , Bucharest , Romania.
Maxime DougadosDepartment of Rheumatology , Paris Descartes University-Hôpital Cochin, Assistance Publique-hôpitaux de Paris-INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité , Paris , France.
Bernard CombeDepartment of Rheumatology , Lapeyronie Hospital, Montpellier 1 University , Montpellier , France.
Robert LandewéClinical Immunology and Rheumatology Department , Academic Research Center/University of Amsterdam, Atrium Medical Center Heerlen , Heerlen , The Netherlands.
Carina MihaiDepartment of Internal Medicine and Rheumatology , Cantacuzino Clinical Hospital , Bucharest , Romania.
Francis BerenbaumUniversity Pierre et Marie Curie Paris VI, 7 quai Saint Bernard , Paris , France ; Department of Rheumatology , 2 AP-HP Saint-Antoine hospital, and Department Hospitalo-Universitaire Inflammation-Immunopathology-Biotherapy (I2B) , Paris , France.
Xavier MarietteDepartment of Rheumatology , Hôpitaux Universitaires Paris Sud, Université Paris Sud, AP-HP, INSERM U1012 , Le Kremlin-Bicêtre , France.
Ron WolterbeekDepartment of Medical Statistics and Bioinformatics , Leiden University Medical Center , Leiden , The Netherlands.
Désirée van der HeijdeDepartment of Rheumatology , Leiden University Medical Centre , Leiden , The Netherlands.
Institutul Cantacuzino · ROLeiden University Medical Center · NLHôpital Saint-Antoine · FRHôpitaux Universitaires Paris-Ouest · FRInserm · FRUniversité de Montpellier · FRUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the prevalence of comorbidities in early rheumatoid arthritis (ERA) and early axial spondyloarthritis (ESpA) versus the general population.

methodsBaseline data of 689 patients with ERA from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) cohort (age 48.2±12.1 years, symptoms duration 14.2±14.5 weeks) and 645 patients with ESpA from Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR; age 32.8±8.4 years, axial symptoms duration 79.0±45.7 weeks) were analysed. Metabolic and cardiovascular diseases (CVD), infections and neoplasia were determined in each cohort. The prevalence (95% CI) of several comorbidities was compared with that in the French general population. For patients without CVD, the 10-year risk of developing CVD was calculated using the Framingham and SCORE equations. The heart age was calculated using the 2008 Framingham points system.

results42% of patients with ERA and 20.3% of patients with ESpA had at least 1 comorbidity; the most common were arterial hypertension (AHT) and dyslipidaemia. AHT prevalence (95% CI) in ERA (18.2% (15.5% to 21.3%)), but not in ESpA (5.08% (3.57% to 7.14%)), was significantly increased (p<0.05) compared with the general population (7.58%). Prevalence of tuberculosis history was higher in ERA (4.7% (3.3% to 6.6%)), and ESpA (0.99% (0.4% to 2.3%)) than in the general population (0.02%; both p<0.05). No differences were observed in malignancies, coronary heart disease or diabetes. In ERA, among patients without a history of CVD, an intermediate to high CVD risk was found. The heart age exceeded the real age by 4.1±9.6 years in ERA and by 2.1±7.0 years in ESpA (p<0.001).

conclusionsWe found an increased prevalence of AHT and tuberculosis history in ERA and ESpA, and an increased CVD risk. These results should prompt rheumatologists to check these comorbidities early in the disease.

Indexed as

Cardiovascular DiseaseRheumatoid FactorSpondyloarthritisTuberculosis

Identifiers

PMID26535145
PMCPMC4623372
OpenAlexW2193195521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.